Compare AbbVie Inc (ABBV) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ProShares Ultra QQQ ETF — how do they compare? AbbVie Inc trades at $253.62 (market cap $449.91B), while ProShares Ultra QQQ ETF trades at $89.49. The key difference: AbbVie Inc pays a 2.72% dividend while ProShares Ultra QQQ ETF pays none, and AbbVie Inc is trading nearer its 52-week high, ProShares Ultra QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | QLD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $100.53 |
52-Week Low | $184.85 | $57.16 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
QLD, the ProShares Ultra QQQ ETF, trades at $93.12, up 2.8% today, reflecting strong bullish momentum with a technical buy signal from moving averages. As a 2x leveraged ETF tracking the Nasdaq-100, it amplifies returns but carries inherent volatility risks. Recent news highlights its long-term performance, with over 10,000% total return since inception, though it experienced significant drawdowns historically.
The outlook for QLD is tied to tech sector strength, with AI optimism and easing geopolitical tensions supporting growth. However, leveraged ETFs like QLD are high-risk tactical instruments unsuitable for long-term holdings due to daily rebalancing effects. Investors should weigh potential amplified gains against the risk of sharp declines in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
